



IPW

I certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:
Commissioner for Patents, P.O. Box 1450
Alexandria, VA 22313 on June 29, 2007.

Frank C Eisenschenk

Frank C. Eisenschenk, Ph.D., Patent Attorney

SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT
Examining Group
Patent Application
Docket No. ARS-127
Serial No. 10/576,509

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Phillippe Chatellard, Markus Imhof
Serial No. : 10/576,509
Filed : April 19, 2006
For : Minimal DNA Sequence Acting as a Chromatin Insulator and its Use in Protein Expression

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §§1.97 AND 1.98


Sir:

In accordance with 37 CFR §1.56, the references listed on the attached form PTO/SB/08 are being brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application. A copy of each cited reference is enclosed.

It is respectfully requested that the references cited on the attached form PTO/SB/08 be considered in the examination of the subject application and that their consideration be made of record.

Applicants respectfully assert that the substantive provisions of 37 CFR §§1.97 and 1.98 are met by the foregoing statement.

Respectfully submitted,



Frank C. Eisenschenk, Ph.D.
Patent Attorney
Registration No. 45,332
Phone No.: 352-375-8100
Fax No.: 352-372-5800
Address: P.O. Box 142950
Gainesville, FL 32614-2950

FCE/gyl

Attachments: Form PTO/SB/08; copies of references cited therein.



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO
**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

1

of

2

Complete if Known

Application Number	10/576,509
Filing Date	April 19, 2006
First Named Inventor	Philippe Chatellard
Group Art Unit	
Examiner Name	

Attorney Docket Number

ARS-127

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R1	BURGESS-BEUSSE, B. et al. "The Insulation of Genes From External Enhancers and Silencing Chromatin", <i>PNAS</i> , December 10, 2002, pp. 16433-16437, Vol. 99, Suppl. 4.	
	R2	CHUNG, J. H. et al. "A 5' Element of the Chicken β -Globin Domain Serves as an Insulator in Human Erythroid Cells and Protects Against Position Effect in <i>Drosophila</i> ", <i>Cell</i> , August 13, 1993, pp. 505-514, Vol. 74.	
	R3	CIANA, P. et al. "Engineering of a Mouse for the <i>in Vivo</i> Profiling of Estrogen Receptor Activity", <i>Molecular Endocrinology</i> , 2001, pp. 1104-1113, Vol. 15, No. 7.	
	R4	SUN, F.-L. et al. "Putting Boundaries on Silence", <i>Cell</i> , November 24, 1999, pp. 459-462, Vol. 99.	
	R5	BELL, A. C. et al. "Stopped at the Border: Boundaries and Insulators", <i>Current Opinion in Genetics & Development</i> , 1999, pp. 191-198, Vol. 9.	
	R6	RECILLAS-TARGA, F. et al. "Positional Enhancer-Blocking Activity of the Chicken β -Globin Insulator in Transiently Transfected Cells", <i>PNAS</i> , December 7, 1999, pp. 14354-14359, Vol. 96, No. 25.	
	R7	IZUMI, M. et al. "Homogeneous Tetracycline-Regulatable Gene Expression in Mammalian Fibroblasts", <i>Journal of Cellular Biochemistry</i> , 1999, pp. 280-289, Vol. 76.	
	R8	DE WET, J. R. et al. "Cloning of Firefly Luciferase cDNA and the Expression of Active Luciferase in <i>Escherichia coli</i> ", <i>Proc. Natl. Acad. Sci. USA</i> , December 1985, pp. 7870-7873, Vol. 82.	
	R9	WOOD, K. V. et al. "Synthesis of Active Firefly Luciferase by <i>in Vitro</i> Translation of RNA Obtained From Adult Lanterns", <i>Biochemical and Biophysical Research Communications</i> , October 30, 1984, pp. 592-596, Vol. 124, No. 2.	
	R10	BLACKWOOD, E. M. et al. "Going the Distance: A Current View of Enhancer Action", <i>Science</i> , July 3, 1998, pp. 60-63, Vol. 281.	
	R11	LI, Q. et al. "Locus Control Regions Coming of Age at a Decade Plus", <i>TIG</i> , October 1999, pp. 403-408, Vol. 15, No. 10.	
	R12	MAZUMDER, B. et al. "Translational Control by the 3'-UTR: The Ends Specify the Means", <i>Trends in Biochemical Sciences</i> , February 2003, pp. 91-98, Vol. 28, No. 2.	
	R13	MOUNTFORD, P. S. et al. "Internal Ribosome Entry Sites and Dicistronic RNAs in Mammalian Transgenesis", <i>TIG</i> , May 1995, pp. 179-184, Vol. 11, No. 5.	

Examiner Signature	Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
Sheet	2	of	2	Application Number	10/576,509
				Filing Date	April 19, 2006
				First Named Inventor	Philippe Chatellard
				Group Art Unit	
				Examiner Name	
				Attorney Docket Number	ARS-127

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
	R14	SCHÜMPERLI, D. et al. "Efficient Expression of <i>Escherichia coli</i> Galactokinase Gene in Mammalian Cells", <i>Proc. Natl. Acad. Sci. USA</i> , January 1982, pp. 257-261, Vol. 79.		
	R15	ZHU, W.-Y. et al. "The Rate of Folate Receptor Alpha (FR α) Synthesis in Folate Depleted CHL Cells is Regulated by a Translational Mechanism Sensitive to Media Folate Levels, While Stable Overexpression of its mRNA is Mediated by Gene Amplification and an Increase in Transcript Half-Life", <i>Journal of Cellular Biochemistry</i> , 2001, pp. 205-219, Vol. 81.		
	R16	ASSARAF, Y. G. et al. "Characterization of the Coexisting Multiple Mechanisms of Methotrexate Resistance in Mouse 3T6 R50 Fibroblasts", <i>The Journal of Biological Chemistry</i> , March 25, 1992, pp. 5776-5784, Vol. 267, No. 9.		
	R17	ABBATE, J. et al. "Bifunctional Protein Conferring Enhanced Green Fluorescence and Puromycin Resistance", <i>BioTechniques</i> , August 2001, pp. 336-340, Vol. 31, No. 2.		
	R18	SHOTWELL, M. A. et al. "Regulation of Amino Acid Transport System L in Chinese Hamster Ovary Cells", <i>The Journal of Biological Chemistry</i> , March 25, 1982, pp. 2974-2980, Vol. 257, No. 6.		
	R19			
	R20			
	R21			
	R22			
	R23			
	R24			
	R25			

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.